I.m

ILD with a granulomatous component

(Fr: PnP avec granulomes). 2018 review at PMID 29698718. Characteristically nonnecrotizing, noninfectious, sterile granulomas. Although this is a pathologic pattern, the condition is suspected on a miliary appearance on imaging. Hilar/mediastinal lymphadenopathy can be present. May mimic pulmonary and/or systemic sarcoidosis. Concomittant skin lesions may show granulomas. A confirmarptory lung biopsy may be required (See under Pathology XIV). Careful exclusion of mycobacterial, fungal and Pneumocystis infection is crucial (See PMID 10678649, 18054121, 17257125).

Last update : 01/01/1970
 

Causative drugs

41

Lamotrigine

1

MTOR inhibitors

1

Mesalazine-Mesalamine-5-aminosalicylic acid-5-ASA

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx) IV.j IV - Airway involvement
IV.j - Bronchiolitis (a clinical-imaging pattern suggestive of) IV.k IV - Airway involvement
IV.k - Bronchiectasis IV.ad IV - Airway involvement
IV.ad - Large airway inflammation - Tracheitis (w/wo tissue eosinophilia) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative) X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension XII.q XII - Cardiovascular involvement / toxicity
XII.q - Pericarditis (see also under XIIc) XII.bf XII - Cardiovascular involvement / toxicity
XII.bf - Myopericarditis (see under XIIc/d/g) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.z XV - Pathology
XV.z - Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn) XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.ay XVI - Imaging
XVI.ay - Imaging: Asymmetrical, predominantly unilateral involvement XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Methotrexate

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain) V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion V.s V - Pleural and/or pericardial involvement
V.s - Serositis - Polyserositis VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.aj VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.aj - Endobronchial lymphoproliferative disorder X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XIII.g XIII - Neoplastic conditions
XIII.g - Lymphomatoid granulomatosis (pulmonary, endothoracic) XIII.k XIII - Neoplastic conditions
XIII.k - Lymphoproliferative disease (extrathoracic) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.w XV - Pathology
XV.w - Path: Pulmonary edema (see also II/IIa) XV.bq XV - Pathology
XV.bq - Path: Lymphoproliferative disease, endothoracic XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules XVI.bc XVI - Imaging
XVI.bc - Imaging: Intrathoracic lymph node enlargement XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
3

Pembrolizumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis III.l III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.l - Alveolar hemorrhage, localized (e.g. lobar) IV.d IV - Airway involvement
IV.d - Cough (lone) IV.j IV - Airway involvement
IV.j - Bronchiolitis (a clinical-imaging pattern suggestive of) IV.k IV - Airway involvement
IV.k - Bronchiectasis IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx) IV.t IV - Airway involvement
IV.t - Sptutum production - Bronchorrhea - 'Bronchitis' IV.y IV - Airway involvement
IV.y - Eosinophilic airway disease (asthma, bronchitis, bronchiolitis) IV.ac IV - Airway involvement
IV.ac - Exacerbation or deterioration of preexisting asthma IV.ad IV - Airway involvement
IV.ad - Large airway inflammation - Tracheitis (w/wo tissue eosinophilia) V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative) VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy VIII.q VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.q - Tongue involvement (edema, glossitis, hematoma) VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.ah X - Systemic/Distant conditions, syndromes and reactions
X.ah - Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome - Cytokine storm X.aw X - Systemic/Distant conditions, syndromes and reactions
X.aw - Connective tissue disease X.ax X - Systemic/Distant conditions, syndromes and reactions
X.ax - Scleroderma X.ay X - Systemic/Distant conditions, syndromes and reactions
X.ay - Polymyalgia rheumatica XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi) XV.bb XV - Pathology
XV.bb - Path: Airway inflammation XV.cw XV - Pathology
XV.cw - Path: Myocardial vasculitis XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse) XVI.z XVI - Imaging
XVI.z - Imaging: A large nodule or a mass XVI.ai XVI - Imaging
XVI.ai - Imaging: A 'tree-in-bud' pattern XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma) XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary/systemic infection XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
1

Pemetrexed

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain) X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.af X - Systemic/Distant conditions, syndromes and reactions
X.af - Thrombotic microangiopathy XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.w XV - Pathology
XV.w - Path: Pulmonary edema (see also II/IIa) XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Perindopril

1

Pirfenidone

1

Sirolimus

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.d IV - Airway involvement
IV.d - Cough (lone) IV.l IV - Airway involvement
IV.l - Bronchial stump dehiscence V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative) VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XV.m XV - Pathology
XV.m - Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern) XV.n XV - Pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern) XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis XV.bf XV - Pathology
XV.bf - Path: Pulmonary necrotizing granuloma or granulomas XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Sulfasalazine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic IV.y IV - Airway involvement
IV.y - Eosinophilic airway disease (asthma, bronchitis, bronchiolitis) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative) VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant) XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

TNF-alpha antagonists / inhibitors

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.d III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apnea IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction/damage X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.p X - Systemic/Distant conditions, syndromes and reactions
X.p - Serum sickness-like reaction X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.x X - Systemic/Distant conditions, syndromes and reactions
X.x - Subclinical ANCA positivity X.ae X - Systemic/Distant conditions, syndromes and reactions
X.ae - Antisynthetase antibodies (ASA) - ASA syndrome XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XV.cs XV - Pathology
XV.cs - Path: Pleural granulomas XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XVII.v XVII - Infections & related conditions
XVII.v - Strongyloides stercoralis hyperinfection (w/wo DAH) XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus pulmonary and/or systemic infection XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation) XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis) XVII.ak XVII - Infections & related conditions
XVII.ak - Mycobacterium leprae infection (Leprosy)
2

Ustekinumab

1

Vemurafenib

1

Venlafaxine

1

Vildagliptin

2

Waterpipe (narghile, shisha) smoking

1

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies